Phoenix, AZ – According to filings with the U.S. Securities and Exchange Commission, Cellebration Life Sciences is raising $20,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Tim Kopatich played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cellebration Life Sciences

Cellebration’s mission is to offer and administer stem-cell based therapies which are highly specialized to treat specific degenerative conditions and directly target the area of concern in rejuvenation therapies. In our science partner’s treatment centers, the medical techniques have been extensively researched and the protocols perfected by leading scientists, physicians, and medical professionals. Regenerative cell therapy consists of a comprehensive evaluation of health conditions with the highest level of expertise to ensure the implementation of a considerably customized stem cell-based therapy. Our clinicians are licensed to treat patients for diseases and degenerative conditions using autologous (their own) adult stem cells and allogeneic (other) adult stem cells. Cellebration is a leading private organization in collaboration with international scientific leaders in the field of stem cell research and technologies for stem cell therapy.

To learn more about Cellebration Life Sciences, visit http://cellebrationlifesciences.com/

Contact:
Tim Kopatich, Chief Executive Officer
858-337-9678
https://www.linkedin.com/in/timothy-kopatich-887297b/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved